Bonus issue alert! Last day to buy this microcap pharma stock that rallied 200% in one year
Microcap pharma company Fredun Pharmaceuticals has fixed July 16 (Thursday) as the record date for its 2:1 bonus issue, making today the last day for
Microcap pharma company Fredun Pharmaceuticals has fixed July 16 (Thursday) as the record date for its 2:1 bonus issue, making today the last day for investors to buy the stock and become eligible for the bonus shares.Only those shareholders who hold Fredun Pharmaceuticals shares in their demat accounts as of Thursday will be eligible to receive the bonus shares. As per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue. This makes today the last day to buy the stock to be eligible for the bonus shares.All about Fredun Pharmaceuticals’ bonus issueFredun Pharmaceuticals had announced a 2:1 bonus issue in May, saying the move reflects its strong financial performance and confidence in its future growth.
Under the issue, eligible shareholders holding the company's shares as of the record date will receive two bonus shares of Rs 10 face value for every one share held.Fredun said that the strategic intent of the bonus issue was to reward shareholders for their sustained confidence and long-term commitment to the company’s growth vision, as well as signal management’s confidence in the structural earnings growth and long-term scalability of the business.“The recommendation of a 2:1 bonus issue reflects the strong momentum we have built and our confidence in sustaining this growth trajectory. With robust performance across revenue and profitability, and continued progress in diversifying into higher-value segments such as nutraceuticals, cosmeceuticals and pet healthcare, we are strengthening the quality and scalability of our business.
This bonus is a way of sharing our progress with shareholders while reinforcing our commitment to consistent, long-term value creation,” said Fredun Medhora, Managing Director of the company.Fredun Pharma share priceFredun Pharma shares dropped over 1% on Wednesday morning to trade at around Rs 2,820 apiece. The stock has overall gained around 8% in the past five days and 22% in the past one month.The shares of the company have jumped 84% in 2026 so far, and nearly 200% in one year. In the longer term, the stock delivered 590% returns over five years. The company currently has a market capitalisation of more than Rs 1,559 crore.Also read: Stocks to buy in 2026 for long term | HCL Tech, Indian Hotels among 5 stocks that could give 10-20% return(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own.
The BriefWire